Vítězslav Bryja

11PUBLICATIONS
24CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cellular immunologyHaematological tumoursPredictive and prognostic markersEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 12, 2026
Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

|Aug 09, 2024
Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy.

Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová

|Nov 28, 2022
A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia.

Pavel Vodárek, Dominika Écsiová, Vladimíra Řezáčová

|Jul 02, 2021
Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?

Lukáš Smolej, Pavel Vodárek, Dominika Écsiová

|Feb 22, 2021
Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q-lite by the Czech CLL Study Group.

Lukáš Smolej, Yvona Brychtová, Eduard Cmunt

|Dec 06, 2020
External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score.

Lukáš Smolej, Peter Turcsányi, Zuzana Kubová

Pageof 2

Frequent Collaborators

5 joint publications

Martin Šimkovič

4 joint publications

Pavel Vodárek

3 joint publications

Dominika Écsiová

3 joint publications

Pavel Žák